AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05544396 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: probiotic
Description: probiotic group give probiotics (2 packs per day) for 6 months.
Study NCT05544396 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: probiotic
Description: probiotic group give probiotics (2 packs per day) for 6 months.
Study NCT05360602 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Alpha Lipoic Acid plus the standard care for post-PCI MI
Description: Intravenous and oral administration of Alpha Lipoic Acid 600 mg plus the standard care for post-PCI MI which will include the required antiplatelet (Dual Antiplatelet Therapy; DAPT), anticoagulants, and anti-ischemic measures (high-intensity statin, ACEI, or aldosterone) as per latest guidelines recommendations.
Study NCT05360602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: The standard care for post-PCI MI
Description: will include the required antiplatelet (Dual Antiplatelet Therapy; DAPT), anticoagulants, and anti-ischemic measures (high-intensity statin, ACEI, or aldosterone) as per latest guidelines recommendations.
Study NCT05592522 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: External oblique intercostal block
Description: EOI block:Under guidance of the linear high frequency transducer, sagittal plane between anterior axillary line and midclavicular line at the level of the 6th rib, In-plane approach between external oblique and intercostal muscles Hydrodissection with 30 ml of 0.25% bupivacaine hydrochloride .
Study NCT05592522 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oblique subcostal TAP block
Description: OSTAP block: The needle was inserted in plane through the rectus adjacent to costal margin Once the tip of the needle was visualized in between the rectus muscle and transversus abdominus muscle and negative pressure aspiration was demonstrated, 30 ml bupivacaine 0.25% was deposited within the plane and hydrodissection was noted.
Study NCT05592522 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Posterior Rectus sheath block
Description: Posterior rectus sheath block: Under linear ultrasound probe, the needle was advanced gradually through the rectus muscle posteriorly toward its medial edge, approaching the rectus sheath. After negative aspiration,12.5 mL bupivacaine 0.25% was injected until the rectus muscle was separated from the posterior rectus sheath by hydrodissection.
Study NCT06048614 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Saline Enema (SE)
Description: infant who allocated with intervention group will proceed with SE with normal saline (20-40ml/kg twice daily) at 48 hours of age. Then continue until 2 days of yellow stools/ 110ml/kg/day of oral feeds; whichever is earlier.~SE are recommended if baby do not do bowel opening (BO) for 2 days before reaching full feeds~Failure to resolve the MOP with SE will be designated as treatment failure and managed with contrast enema or Laparotomy by paediatric surgeons, following a formal referral.GS is not allowed in intervention arm
Study NCT06048614 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycerin Suppository
Description: Infants randomized to GS received the standard management protocol for meconium retention in the unit. GS (2,000 mg, a quarter unit, four doses 12 h apart) were administered to infants earliest at 48 hour to 72 hours of birth, with subsequent once-daily GS being administered at the discretion of the managing team. Infants who were diagnosed with meconium obstruction later in the first 2 weeks of life were also treated with glycerin suppositories for 48 hrs, with subsequent once-daily GS being administered at the discretion of the managing team.~Infants who failed to respond to glycerin suppositories were referred to the surgical team by the managing team The subsequent management of meconium retention was at the surgeon's discretion and included continued GS by the surgical team, contrast enema or surgical interventions performed in escalating order as mentioned.
Study NCT04969003 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Short videos
Description: Intervention videos will each be of 90-second duration and feature four underage professionals (ages 16) acting as simulated patients. All videos will focus on an empowered presenter with depression sharing their personal story regarding depression and describe how social supports from family, friends, and community, as well as professional help assisted them in overcoming symptoms of their illness. The actors will include a transgender male, a cis-gender male, a transgender female, and a cis-gender female.
Study NCT06423729 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicorandil 10 MG
Description: Patients will receive oral Nicorandil 10 MG twice daily in addition to 2nd generation sulfonylureas , for 3 months.
Study NCT05635643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHS-114
Description: CHS-114
Study NCT05635643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: toripaliamab
Description: toripalimab-tpzi
Study NCT05879211 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Feedback
Description: Providers will receive detailed feedback about the timing, quality, and frequency of their goals of care communication with patients
Study NCT06659887 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasal cannula
Description: After induction, bag-mask ventilation with 100% oxygen and flow rates of 6 L/ min will be carried out until the expired oxygen concentration will be >90%, saturation of oxygen was 100%, and end tidal carbon dioxide was 30-40 mmHg. Once this will be reached, bag-mask ventilation will be stopped and apneic oxygenation will be initiated for 3 minutes
Study NCT06611137 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: SBRT+Toripalimab Plus Docetaxel and Cisplatin
Description: All participants will receive SBRT (18Gy/3 fractions, QOD ) to gross tumor and metastatic lymph nodes, followed by neoadjuvant chemoimmunotherapy of Toripalimab (240mg) Plus Docetaxel (75mg/m2, q3w) and Cisplatin (75mg/m2, q3w) for 3 cycles. If tumor has complete or partial response at 2 weeks after the last course of neoadjuvant chemotherapy, participants will then receive intensity modulated radiotherapy (54Gy/27 fractions). If tumor is stable or progressive, participants will receive radical resection with or without postoperative intensity modulated radiotherapy when necessary.
Study NCT06611514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prasterone (DHEA)
Description: Prasterone 6.5 mg vaginal tablets
Study NCT06608888 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: MRI
Description: Multimodal MRI technology is a method that combines various magnetic resonance imaging techniques, providing more comprehensive images and information about human tissues and organs. These different imaging techniques include, but are not limited to:~Structural MRI (sMRI): Provides information about the types of brain tissues, such as gray matter, white matter, and cerebrospinal fluid.~Functional MRI (fMRI): Dynamically measures the hemodynamic response related to brain neural activity, commonly used to study brain functional activities.~Diffusion Tensor Imaging (DTI): Offers information on the structural connections between brain regions, which can be used to study the neural fiber pathways of the brain
Study NCT06614322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: 300mg/day pregabalin capsule
Study NCT06614322 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: 60mg/day duloxetine capsule
Study NCT06614322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo capsule
Study NCT06613503 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AI-supporter
Description: rticipants in the experimental group will use the AI-supporter, an intelligent excretion management robot. This device utilizes AI-driven visual recognition technology to automatically detect urine and feces, followed by a cleaning and drying process. When the AI-supporter detects excretion, it activates an automated sequence that washes, dries, and sanitizes the perineal area without requiring the caregiver to remove the diaper. The AI-supporter also records relevant data, such as the time, frequency, and weight of excretion, for further analysis. This intervention is designed to reduce the incidence of urinary tract infections (UTIs) and incontinence-associated dermatitis (IAD), as well as lessen the workload for caregivers
Study NCT05504343 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Intensity SL Intraocular Lens
Description: Cataract surgery and intraocular lens implantation
Study NCT06615037 — intervention group
Intervention type: OTHER
Intervention: Assess Hip joint strength by Biodex isokinetic dynamometer (System 4 Pro)
Description: Assessment of the strength of hip flexors and extensors muscles:~* Participants will be in a supine-lying position, the highest reliability (ICC = 0.90) according to the results of the meta-analysis (Contreras et al., 2021).~* Seat orientation 0°.~* Dynamometer tilt 0° and orientation 0°.~* The axis of the dynamometer on the greater trochanter of the femur.~* The test parameters included a 0-90 degree range of motion.~* During the isokinetic testing movement, the hip was first flexed from a neutral (starting) position to 90° (for hip flexion) and then the direction of the movement was reversed (for hip extension)~* Angular speed at 120°/s which shows excellent reliability (ICC = 95%) with concentric contraction mode (Contreras et al., 2021) .
Study NCT06118710 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone prior to paclitaxel infusion according to local care standards.
Study NCT06118710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H1 Antihistaminics
Description: Clemastine or Cetirizine prior to paclitaxel infusion according to local care standards
Study NCT06118710 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: H1 Antihistaminics
Description: Clemastine or Cetirizine prior to paclitaxel infusion according to local care standards
Study NCT06259201 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vagus Nerve Stimulation
Description: Vagal nerve stimulation (VNS) involves the use of a device to stimulate the vagus nerve with electrical impulses twice per day (AM \& PM) for two minutes each. It is an approved treatment for treatment resistant epilepsy and depression.
Study NCT05126862 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MindTrails
Description: MindTrails is a web-based cognitive bias modification intervention. Training sessions are designed to encourage cognitive flexibility through repeated practice assigning benign resolutions to ambiguous, anxiety-provoking situations.
Study NCT06157398 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Increased EPA, DHA, fruit, and vegetable intake
Description: Participants will receive food deliveries for approximately 4-weeks via online ordering, meal delivery, and dietician counseling.
Study NCT06614868 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Up to 16 session of unstructured counseling therapy informed by Acceptance and Commitment Therapy tradition.
Study NCT05965362 — intervention group
Intervention type: OTHER
Intervention: Observational; No Interventions were given.
Description: Observational; No Interventions were given.
Study NCT06695728 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise
Description: It consists of exercises to be done with the exoskeleton. These are; jumping exercise, squat, sit-stand and forward bending exercises.
Study NCT06696625 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcutaneous Auricular Vagus Nerve Stimulation
Description: taVNS device (Elmmedicare, EC100, Shenzhen, China) was used to apply stimulation for patients.~Stimulation parameters comprised an electrical current of 1 mA at a frequency of 20 Hz, with a waveform width of 1 ms. Repurposed off-the-shelf devices were utilized for this purpose, with the stimulator generating single square-wave pulses lasting 1 ms each. Enhancing conductivity was achieved by wiping the ear with tap water. The electrodes were placed on the cymba conchae and concha around the affected ear, which is the region of rich vagus nerve branch distribution.
Study NCT06696625 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcutaneous Auricular Vagus Nerve Stimulation
Description: taVNS device (Elmmedicare, EC100, Shenzhen, China) was used to apply stimulation for patients.~Stimulation parameters comprised an electrical current of 1 mA at a frequency of 20 Hz, with a waveform width of 1 ms. Repurposed off-the-shelf devices were utilized for this purpose, with the stimulator generating single square-wave pulses lasting 1 ms each. Enhancing conductivity was achieved by wiping the ear with tap water. The electrodes were placed on the cymba conchae and concha around the affected ear, which is the region of rich vagus nerve branch distribution.
Study NCT05893979 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spectacle Lenses
Description: Standard Spectacle Lenses
Study NCT06255834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IPG11406
Description: IPG11406 Activity: An antagonist of the GPR183 Dosage form: Tablet Strength: 0.5 mg, 10 mg and 40 mg Storage：15 \~ 25 °C in a tightly sealed container, protect from light Administration: In each cohort, IPG11406 or placebo tablets are orally administered once on Day 1 (Part A) or daily for 10 days from Day 1 to Day 10 (Part B) in a fasted state. Oral doses will be administered with 240 ml of water. Tablets should not be chewed or crushed.~Participants in the FE Cohort will receive a second single dose of IPG11406 following a standardized high fat meal upon ≥4 days washout period after the first dose.~IPG11406 Placebo Placebo tablets: tablets identical to IPG11406 tablets
Study NCT04920136 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Strip Free gingival graft (SGG) + Acellular Dermal Matrix graft (ADM)
Description: A horizontal incision is then placed at the middle of residual KT. Two vertical releasing incisions are followed to allow for apical displacement of the flap. The flap will be then elevated with a split-thickness flap beyond the mucogingival junction where it is sutured at this apical position using a mattress (5-0, monocryl) suture. The recipient site should ideally retain intact periosteum that is firmly attached to bone with no loose fibers, no irregularities and no perforations.
Study NCT04920136 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Free Gingival graft
Description: Two vertical incisions are made, and a partial thickness flap are designed to provide a firm and immobile periosteal bed. The raised partial thickness flap will be excised. Muscle and unattached connective tissue fibers are thoroughly scraped with a scalpel to prevent graft mobility. Autogenous FGG was harvested with #15C scalpel blade from hard palate at the same side randomly selected to receive the FGG. Donor area was sutured with 5-0 gut sutures. FGG, is placed and stabilized with simple interrupted 5-0 vicryl sutures at recipient site coronal border and horizontal or periosteal anchorage sutures over the graft.
Study NCT05997680 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-child yoga
Description: The 45-minute yoga sessions are structured to include an opening and a closing ritual that remain the same throughout the 8 weeks, between which an active and a calming parts are scheduled. The active and calming parts are embedded in stories that align with the developmental level and interests typical of 4-to-6-year-olds. Each session is clearly structured with each exercise and transition well described in the Yoga for Little Hearts Yoga Program Manual. In addition to the yoga sessions, at-home exercises (5 min) including breathing, meditation and mindfulness activities will be explained to participants. We will ask them to practice them at home at least 3 times every week, for the 8-week duration of the intervention. Including the yoga session and home exercises, the 8-week intervention thus includes at least 60 minutes of yoga per week. Parents will be encouraged to pursue the at-home exercises after the end of the 8-week yoga program, up to the 6-month follow-up.
Study NCT04586959 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Surgery with UM
Description: The experimental group will have MIS with the placement of a uterine manipulator
Study NCT04586959 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery without UM
Description: The control group will have MIS without the placement of a uterine manipulator
Study NCT05959746 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI-STROKE application
Description: Complete neurological exam of stroke patients will be filmed by healthcare workers and themselves using the AI-STROKE application
Study NCT06139211 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: JS015
Description: JS015 will be administered intravenously (IV) on days 1 and 15 every 28 day cycle, or day 1 every 21 day cycle, based on different combined chemotherapy.
Study NCT06139211 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Toripalimab
Description: Toripalimab will be administered intravenously (IV) on day 1 every 21 day cycle.
Study NCT06139211 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be administered intravenously (IV) on day 1 every 21 day cycle.
Study NCT06139211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan will be administered intravenously (IV) on days 1 and 15 every 28 day cycle.
Study NCT06139211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Capecitabin will be administered orally twice daily from day 1 to 14 every 21 day cycle.
Study NCT06139211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered intravenously (IV) on day 1 every 21 day cycle.
Study NCT06139211 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab of 5mg/kg will be administered intravenously (IV) on days 1 and 15 every 28 day cycle, or7.5mg/kg on day 1 every 21 day cycle, based on different combined chemotherapy.
Study NCT06139211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Fluorouracil will be administered intravenously (IV) on days 1 and 15 every 28 day cycle.
Study NCT06139211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin will be administered intravenously (IV) on days 1 and 15 every 28 day cycle.
Study NCT06139211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be administered intravenously (IV) on days 1 and 8 every 21 day cycle.
Study NCT06139211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumin-Bound Paclitaxel
Description: Albumin-bound paclitaxel will be administered intravenously (IV) on days 1 and 8 every 21 day cycle.
Study NCT06430346 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Physical activity and resistance training
Study NCT06583239 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Engagement Navigator Service (ENS)
Description: ENS will be a centralized service, staffed by dedicated professional to (1) receive and organize referrals, (2) complete ongoing specialized training in engagement science and evidence-based strategies, (3) provide unbiased support when participants' and/or families' relationships with a CSC program are poor, (4) re-engage participants in CSC or actively connect them with other services if preferred, and (5) continue contact with those who refuse treatment in case they reconsider.
Study NCT06581796 — intervention group
Intervention type: OTHER
Intervention: pepsinogen-1
Description: association between pepsinogen 1 serum level with hyperemesis gravidarum
Study NCT05698459 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: OH2 injection
Description: OH2 injection administered by transcatheter Intraarterial infusion
Study NCT06546969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m2 via intravenous infusion on days 1 and 8 of every 21-day cycle for up to 8 cycles. After the 16 weeks of trial participation, participants will continue chemoimmunotherapy per standard of care.
Study NCT06546969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25mg/m2 via intravenous infusion on days 1 and 8 of every 21-day cycle for up to 8 cycles. After the 16 weeks of trial participation, participants will continue chemoimmunotherapy per standard of care.
Study NCT06546969 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: 1500mg via intravenous infusion on day 1 of every 21-day cycle for up to 8 cycles. After the 16 weeks of trial participation, participants will continue chemoimmunotherapy per standard of care.
Study NCT06546969 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Spatially Fractionated RT
Description: Administered to 1 measurable lesion on cycle 2-day 1
Study NCT06546969 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Hyperthermia
Description: Deep hyperthermia alone will be delivered to the same lesion on cycle 3-day 1 and cycle 4-day 1